Eisai以6000万美元的预付款和潜在里程碑，获得了肺癌药物taletrectinib在美国、中国和日本以外的全球发行权。 Eisai acquires global rights to lung cancer drug taletrectinib outside U.S., China, and Japan, with a $60M upfront payment and potential milestones.

艾赛已获得在欧洲,中东,北非,俄罗斯,土耳其,加拿大,澳大利亚,新西兰和几个亚洲国家开发和销售塔莱特雷克提尼布的独家权利,扩大其全球范围超越美国,中国和日本. Eisai has acquired exclusive rights to develop and sell taletrectinib in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, and several Asian nations, expanding its global reach beyond the U.S., China, and Japan. 该药物自2025年6月以来在美国获得批准,治疗先进的ROS1呈阳性的非小型细胞肺癌。 The drug, already approved in the U.S. since June 2025, treats advanced ROS1-positive non-small cell lung cancer. Eisai将预付6 000万美元,最高达到1.7亿美元里程碑,并支付两位数的版税。 Eisai will pay $60 million upfront, up to $170 million in milestones, and double-digit royalties. 预计2026年初将提交一份欧洲监管申报,并计划提交更多呈件。 A European regulatory filing is expected in early 2026, with additional submissions planned. Nuevation Bio保留了美国的商业权利,并领导全球发展。 Nuvation Bio retains U.S. commercial rights and leads global development. Eisai预计2026年3月之前不会产生任何财政影响。 Eisai expects no financial impact through March 2026.